---
title: "Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential"
description: "Hedge fund Shah Capital is urging Novavax Inc. to consider a sale due to ongoing challenges with its COVID-19 vaccine rollout. Holding a 7.2% stake, Shah believes Novavax's assets could be more valuab"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261116280.md"
published_at: "2025-10-14T17:08:17.000Z"
---

# Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

> Hedge fund Shah Capital is urging Novavax Inc. to consider a sale due to ongoing challenges with its COVID-19 vaccine rollout. Holding a 7.2% stake, Shah believes Novavax's assets could be more valuable under a larger pharmaceutical company, estimating a potential valuation of at least $5 billion. Despite Novavax's market cap of around $1.4 billion, the company has struggled with sales, capturing only 2% of the market last season. Novavax's stock rose 3.07% to $8.89 amid these developments.

**Shah Capital** is reportedly pressing **Novavax Inc.** (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine.

**• NVAX stock is showing exceptional strength. View the charts here.**

The hedge fund holds a 7.2% stake and is the company's second-largest shareholder. The fund said in a Tuesday letter that Novavax's assets could achieve "far greater potential in the hands of a large capable pharma entity."

Shah suggested that major pharmaceutical companies, including **Sanofi SA** (NASDAQ:SNY), **Merck & Co. Inc.** (NYSE:MRK), **GSK Plc** (NYSE:GSK), and **AstraZeneca Plc** (NASDAQ:AZN), could be potential buyers for Novavax.

**Himanshu Shah**, founder and chief investment officer of Shah Capital, told Reuters the company could be valued at "at least $5 billion" based on the commercial potential of its vaccines. As per data from Benzinga Pro, Novavax has a market cap of around of $1.4 billion.

***Also Read: FDA Moves To Publicize Data On Pregnant Women’s Covid Vaccine Side Effects***

He also noted that political conditions and scientific data are currently favorable for the company.

Last year, the fund withdrew its campaign opposing the re-election of three Novavax board members after the company finalized a licensing deal with Sanofi.

"The problem has been the sales," Shah said in his statement to Reuters, pointing to a series of marketing missteps that have hindered Nuvaxovid, Novavax's protein-based COVID-19 vaccine. According to the hedge fund, the shot captured just 2% of the market last season, reflecting underperformance compared with competitors.

As of Oct. 2, Novavax had distributed roughly 7,000 doses of its vaccine, while rivals **Pfizer Inc.** (NYSE:PFE) and **Moderna Inc**. (NASDAQ:MRNA) each rolled out nearly six million shots, Shah noted.

Novavax reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the consensus of $156.29 million.

Novavax revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate in July.

Leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M adjuvant, the vaccine candidate induced robust immune responses in nonhuman primates after either single — or two-dose intranasal (IN) or intramuscular (IM) administration.

**NVAX Price Action**: Novavax stock is up 3.07% at $8.89 at publication on Tuesday.

-   **Albertsons Lifts Profit Outlook, Boosts Share Buyback**

*Photo: Shutterstock*

### Related Stocks

- [NVAX.US - Novavax](https://longbridge.com/en/quote/NVAX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 諾瓦瓦克斯（NASDAQ:NVAX）在 2025 年第三季度的銷售額出人意料 | 疫苗生物技術公司諾瓦瓦克斯醫藥（NASDAQ: NVAX）報告了 2025 年第三季度銷售額為 7045 萬美元，超出華爾街的預期，但同比下降了 16.6%。該公司預計全年收入約為 10.5 億美元。其調整後的每股收益為-1.25 美元，低 | [Link](https://longbridge.com/en/news/271286432.md) |
| 辛巴威修憲草案 擬延長總統姆南加瓦任期至 2030 年 | 辛巴威內閣通過憲法修正草案，計劃將總統姆南加瓦的任期延長至 2030 年。該草案將總統任期從 5 年延長至 7 年，並由國會選出總統，需經國會審議。姆南加瓦的執政黨 ZANU-PF 去年已通過相關計劃，旨在讓其在 2028 年任期屆滿後繼續 | [Link](https://longbridge.com/en/news/275518658.md) |
| 恆地慶祝 50 週年 再辦兩大活動 與 3500 名長幼基層迎新歲 | 恆基地產慶祝成立 50 週年，舉辦了「馬年耆樂團年宴」和「社區同樂日」兩大活動，吸引 3500 名長者、年輕人及基層家庭參與。活動包括團年飯、非物質文化遺產展示、幸運抽獎及兒童表演，旨在營造節慶氛圍並傳遞愛心與正能量。集團與 20 多個非牟 | [Link](https://longbridge.com/en/news/276030098.md) |
| 儲局官員博斯蒂克料今年不減息 稱沃什面臨「艱巨任務」 | 亞特蘭大聯邦儲備銀行行長博斯蒂克預計 2026 年不會減息，認為美國經濟強勁，政策利率應維持在適度限制性水平。他提醒下任主席沃什面臨「艱巨任務」，需說服委員會成員支持其政策。博斯蒂克支持維持基準利率在 3.5% 至 3.75% 區間，認為保 | [Link](https://longbridge.com/en/news/274591136.md) |
| AVAX 上漲的可能性——以下是交易者應關注流動性的原因 | 儘管市場較為平靜，AVAX 生態系統仍吸引了投資者的關注，錄得每月淨流入 1.35 億美元。自 1 月以來，活躍地址激增超過 242%，表明網絡參與度增加。AVAX 的價格從峯值回落超過 84%，穩定在 8.85 美元至 11.86 美元之 | [Link](https://longbridge.com/en/news/275543811.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.